oral ERK1/2 kinase and phosphorylation inhib

Ph. 1/2 candidate for solid tumors

from SBDD from prior lead

Journal of Medicinal Chemistry

Astex Pharmaceuticals, Cambridge, UK

Structure of ASTX029

The Astex ERK1/2 kinase inhibitor, ASTX029, is an oral Ph. I-II candidate for patients with advanced solid tumors. The molecule was derived from fragment screening together with structure-based design. Interestingly,…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: